CLINDAMYCIN HYDROCHLORIDE

Post-LOE

clindamycin hydrochloride

Molecular Devices

ANDAORALCAPSULE

Approved

Nov 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

CLINDAMYCIN HYDROCHLORIDE (clindamycin hydrochloride) by Molecular Devices is clinical pharmacology human pharmacology absorption pharmacokinetic studies with a 150 mg oral dose of clindamycin hydrochloride in 24 normal adult volunteers showed that clindamycin was rapidly absorbed after oral administration. Approved for the treatment of serious infections caused by susceptible anaerobic bacteria, the treatment of serious infections due to susceptible strains of streptococci, pneumococci and 7 more indications. First approved in 2018.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Human Pharmacology Absorption Pharmacokinetic studies with a 150 mg oral dose of clindamycin hydrochloride in 24 normal adult volunteers showed that clindamycin was rapidly absorbed after oral administration. An average peak serum concentration of 2.50 mcg/mL was reached in 45…

Worked on CLINDAMYCIN HYDROCHLORIDE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

CLINDAMYCIN HYDROCHLORIDE

Mechanism of Action

Indications (10)

Clinical Trials (1)